How does KPV work?

KPV is the last three building blocks of alpha-MSH, the chain lysine-proline-valine. This site's profile says it gets into cells and turns down NF-kB, a switch that drives inflammation. Its molecular weight is 342.4 daltons. It is listed as leaving the body quickly (a short half-life). This site's review found no published human trial. The FDA took it off its Category 2 compounding list in April 2026. In July 2026 an advisory panel voted 8 to 6 to recommend it for compounding, against the reviewers. That vote is advice only and is not an approval. The studies cited are in mice with colitis and in cells in a lab. In a dish, tiny amounts of KPV turned down two inflammation signals (NF-kappaB and MAP kinase). In mice, KPV by mouth reduced chemically caused colitis (DSS and TNBS), working through a gut carrier called PepT1. Those animal findings do not transfer into a counted human gut-healing mechanism. This FAQ does not invent a human mechanism. Full record at /compounds/kpv.

Educational use only. This database summarizes published research and is not medical advice. Where a dose appears it is a record of what a trial or clinic ran, or what people describe doing, with its source attached. Nothing here is a recommendation for personal use.

Part of healing and recovery peptides. BPC-157, TB-500, GHK-Cu, and the tissue repair family, including what actually has human data.